期刊
EUROPEAN RESPIRATORY JOURNAL
卷 41, 期 1, 页码 46-52出版社
EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/09031936.00092111
关键词
Asthma; chemokine; eosinophil; late allergic response
资金
- Oxagen Ltd (Abingdon, UK)
CRTH2 (chemoattractant receptor expressed on T-helper (Th) type 2 cells) is a G-protein-coupled receptor expressed by Th2 lymphocytes and eosinophils that mediates prostaglandin (PG)D-2-driven chemotaxis. We studied the efficacy of the oral CRTH2 antagonist 00000459 in steroid-naive asthmatic patients. A randomised, double-blind, placebo-controlled, two-way crossover study of 16 days' treatment with 00000459 (200 mg twice daily) on the late (LAR) and early (EAR) asthmatic responses to bronchial allergen challenge was conducted, with 16 subjects completing the study. There was a 25.4% (95% CI 5.1-45.6%) reduction in the LAR area under the curve (AUC) for change in forced expiratory volume in 1 s with 00000459 compared with placebo (p=0.018) but no effect on the EAR. Sputum eosinophil counts at 1 day post-allergen challenge were lower after 00000459 treatment (p=0.002). PGD(2)-induced blood eosinophil shape change ex vivo was assessed at day 7 (n=7). The AUC of eosinophil shift for 00000459 was lower than placebo; the mean difference was -33.6% (95% Cl -66.8-0.4%; p=0.048). OC000459 treatment inhibited LAR and post-allergen increase in sputum eosinophils. This CRTH2 antagonist appears to inhibit allergic inflammation in asthma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据